Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
This study is designed to investigate whether sympathoinhibition with moxonidine could provide added metabolic benefit compared to the second line therapy in the current guidelines.
Epistemonikos ID: 81c4a013e1386ac71bde7a15fd2998be95f08f5b
First added on: May 07, 2024